Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk Factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1). Available from: https://pubmed.ncbi.nlm.nih.gov/15198963/. Cited 2024 Mar 16.
Ambrosi P, Rolland P, Garçon D. [Homocysteine, a risk factor of atherosclerosis]. Arch Mal Coeur Vaiss. 1996;89(12):1667–71.
Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA. 2004;291(5):565–75. Available from: https://jamanetwork.com/journals/jama/fullarticle/198139. Cited 2024 Mar 16 .
Khandanpour N, Armon MP, Jennings B, Finglas PM, Willis G, Clark A et al. Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. In: Br J Surg. 2009:990–8. https://pubmed.ncbi.nlm.nih.gov/19672935/
Santilli F, Davì G, Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascul Pharmacol. 2016;78:1–9.
Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk of cardiovascular diseases: A Meta-Analysis of randomized controlled trials. J Am Heart Assoc. 2016;5(8):1–18.
Kaye AD, Jeha GM, Pham AD, Fuller MC, Lerner ZI, Sibley GT, et al. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. Adv Ther. 2020;37(10):4149 Available from: https://pubmed.ncbi.nlm.nih.gov/32845472/. Cited 2024 Mar 16.
Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. In: Nitric Oxide – Biology and Chemistry. 2011. pp. 81–8. https://doi.org/10.1002/bjs.6670
Calderon Martinez E, Valdés JRF, Castillo JL, Castillo JV, Montecino RMB, Jimenez JEM et al. Ten Steps to Conduct a Systematic Review. Cureus. 2023;15(12). Available from: https://www.cureus.com/articles/217671-ten-steps-to-conduct-a-systematic-review. Cited 2024 Jan 30.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. Available from: https://www.bmj.com/content/372/bmj.n71. Cited 2023 Dec 13.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. Available from: https://doi.org/10.1186/s13643-016-0384-4.
Cochrane. Handbook for Systematic Reviews of Interventions | Cochrane Training. Available from: https://training.cochrane.org/handbook/currenthttps://training.cochrane.org/handbook/current. Cited 2023 Oct 25.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https://doi.org/10.1136/bmj.l4898
Jackson D, White I, Thompson S. Extending dersimonian and laird’s methodology to perform multivariate random effects Meta-Analyses. Stat Med. 2009;29:1282–97.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
Viechtbauer W, Cheung MWL. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1(2):112–25.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Available from: https://www.bmj.com/content/315/7109/629.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https://doi.org/10.1136/bmj.n71
Zhao X, Feng GC, Ao SH, Liu PL. Interrater reliability estimators tested against true interrater reliabilities. BMC Med Res Methodol. 2022;22(1): 990-998 . https://doi.org/10.1186/s12874-022-01707-5
Mehta KN, Chag MC, Parikh KH, Shah UG, Baxi HA, Chandarana AH et al. Effect of folate treatment on homocysteinemia in cardiac in cardiac patients: A prospective study patients: A prospective study patients: A prospective study patients: A prospective study patients: A prospective study. 2005. Available from: http://journals.lww.com/iphr
Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47(6):1108–16.
Bleie Ø, Strand E, Ueland PM, Vollset SE, Refsum H, Igland J, et al. Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12. Coron Artery Dis. 2011;22(4):270–8.
Liu M, Wang Z, Liu S, Liu Y, Ma Y, Liu Y, et al. Effect of B vitamins supplementation on cardio-metabolic factors in patients with stable coronary artery disease: A randomized double-blind trial. Asia Pac J Clin Nutr. 2020;29(2):245–52.
Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A. Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under Lovastatin treatment: A Double-blind randomized controlled clinical trial. Arch Med Res. 2009;40(5):380–6.
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B 12, and Vitamin B 6 on Clinical Outcome After Percutaneous Coronary Intervention The Swiss Heart Study: A Randomized Controlled Trial. 2002. Available from: http://jama.jamanetwork.com/.
Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355(9203):517-522. https://pubmed.ncbi.nlm.nih.gov/10683000/
VITATOPS Trial Study Group T. B vitamins in patients with recent transient ischaemic attack or stroke in the vitamins TO prevent stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. 2010; Available from: https://www.thelancet.com/neurology.
Van Dijk SC, Enneman AW, Swart KMA, Van Wijngaarden JP, Ham AC, Brouwer-Brolsma EM, et al. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial. J Hypertens. 2015;33(9):1897–906.
Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ et al. Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering. 2002. Available from: http://www.circulationaha.org.
Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588. https://doi.org/10.1056/NEJMoa055227
Toole JF, Malinow MR, Chambless LE, Spence JD, Creed Pettigrew L, Howard VJ et al. Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. 2004. Available from: http://jama.jamanetwork.com/.
Guo H, Chi J, Xing Y, Wang P. Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina. 2009. Available from: http://journals.lww.com/ijmr.
Jonasson T, Öhlin AK, Gottsäter A, Hultberg B, Öhlin H. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease – A prospective randomized study of vitamin supplementation. Clin Chem Lab Med. 2005;43(6):628–34.
Rydlewicz A, Simpson JA, Taylor RJ, Bond CM, Golden MHN. The effect of folic acid supplementation on plasma homocysteine in an elderly population. 2002.
Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in china: the CSPPT randomized clinical trial. JAMA – J Am Med Association. 2015;313(13):1325–35.
Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K et al. Folate Therapy and In-Stent Restenosis after Coronary Stenting. n engl j med. 2004;26. Available from: www.nejm.org.
Liem AH, Van Boven AJ, Veeger NJGM, Withagen AJ, De Medina RMR, Tijssen JGP, et al. Efficacy of folic acid when added to Statin therapy in patients with hypercholesterolemia following acute myocardial infarction: A randomised pilot trial. Int J Cardiol. 2004;93(2–3):175–9.
Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in End-Stage renal disease. J Am Soc Nephrol. 2004;15(2):420–6.
Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, Van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41(12):2105–13.
Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, Van Veldhuisen DJ. Secondary prevention with folic acid: results of the goes extension study. Heart. 2005;91(9):1213–4.
Lonn E. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. 2006.
Righetti M, Serbelloni P, Milani S, Ferrario GM. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in Hemodialysis patients. Blood Purif. 2006;24(4):379–86.
Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD et al. Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease A Randomized Controlled Trial. 2007. Available from: http://jama.jamanetwork.com/.
Vianna ACA, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA et al. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. 2007.
Ebbing M, Bleie Ø, Magne Ueland P, Erik Nordrehaug J, Nilsen DW, Emil Vollset S et al. Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography A Randomized Controlled Trial. 2008. Available from: http://jama.jamanetwork.com/.
Imasa MSB, Gomez NT, Nevado JB. Folic acid-based intervention in non-ST elevation acute coronary syndromes. Asian Cardiovasc Thorac Ann. 2009;17(1):13–21.
Armitage J. Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors. Available from: http://www.jama.com.
Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, Luley C, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation. 2010;121(12):1432–8.
House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A et al. Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy A Randomized Controlled Trial. 2010. Available from: http://jama.jamanetwork.com/.
Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic acid for vascular outcome reduction in transplantation trial. Circulation. 2011;123(16):1763–70.
Righetti M, Ferrario G, Milani S, Serbelloni P, La Rosa L, Uccellini M et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. 2003. Available from: http://www.MedSciMonit.com/pub/vol_9/no_4/3064.pdf.
Nand N, Sharma M, Mittal N. Prevalence of hyperhomocysteinaemia in chronic kidney disease and effect of supplementation of folic acid and vitamin B12 on cardiovascular mortality. J Indian Acad Clin Med. 2013;14. Available from: https://www.researchgate.net/publication/287242975.
Bahmani F, Fatemeh ;, Galougahi R, Vahedpoor Z, Jamilian ; Mehri, Mahmoodi S et al. The Effects of Folic Acid Supplementation on Recurrence and Metabolic Status in Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial IRANIAN MEDICINE. Arch Iran Med. 2018;21. Available from: www.irct.ir.
Maurizi AR, Menduni M, Del Toro R, Kyanvash S, Maggi D, Guglielmi C, et al. A pilot study of d-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol. 2017;54(4):361–5.
El-khodary NM, Dabees H, Werida RH. Folic acid effect on homocysteine, sortilin levels and glycemic control in type 2 diabetes mellitus patients. Nutr Diabetes. 2022;12(1) :33. https://doi.org/10.1038/s41387-022-00210-6
Satapathy S, Bandyopadhyay D, Patro BK, Khan S, Naik S. Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial. Complement Ther Med. 2020;53 :102526.
Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, Swart KMA, Ploegmakers KJ, Zillikens MC, et al. Long-term effects of folic acid and vitamin-B12 supplementation on fracture risk and cardiovascular disease: extended follow-up of the B-PROOF trial. Clin Nutr. 2021;40(3):1199–206.
Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA. 2008;299(17):2027–36.
Cole BF, Baron JA, Sandler RS, Haile RW, Dennis Ahnen DJ, Bresalier RS et al. Folic Acid for the Prevention of Colorectal Adenomas A Randomized Clinical Trial. 2007. Available from: http://jama.jamanetwork.com/.
Mark SD, Wang W, Fraumeni JF, Li JY, Taylor PR, Wang GQ et al. Lowered risks of hypertension and cerebrovascular disease after Vitamin/Mineral supplementation the Linxian nutrition intervention trial. 143. 1996.
Potena L, Grigioni F, Masetti M, Magnani G, Coccolo F, Fallani F, et al. Long-term effect of folic acid therapy in heart transplant recipients: Follow-up analysis of a randomized study. Transplantation. 2008;85(8):1146–50.
Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, Detrano R, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: A randomized controlled trial. Stroke. 2009;40(3):730–6.
Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M et al. Oral High-Dose Multivitamins and Minerals After Myocardial Infarction A Randomized Trial. 2013. Available from: https://www.acpjournals.org/journal/aim.
Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and Omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ. 2011;342(7787):36.
Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: An updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2012;23(8):745–54 Available from: https://www.sciencedirect.com/science/article/abs/pii/S0953620512001793. Cited 2025 Aug 9 .
Zhang N, Zhou Z, Chi X, Fan F, Li S, Song Y, et al. Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide. Clin Nutr. 2024;43(7):1706–16.
Tighe P, Ward M, McNulty H, Finnegan O, Dunne A, Strain JJ, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr. 2011;93(1):11–8.
Yuan S, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med. 2021;19(1) :97.
Bushnell C, Kernan WN, Sharrief AZ, Chaturvedi S, Cole JW, Cornwell WK et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2024; Available from: https://doi.org/10.1161/STR.0000000000000475.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation NLM (Medline). 2019;140:e596-646.